Guggenheim’s $78 target on ELVN

ELVN Enliven Therapeutics Inc

$40.6 → $78 (+92%) by Oct 2027

Buy · reiterates · said Oct 8, 2026 · 12-month default horizon

Open: judged on the close on Oct 8, 2027

The article this target came from

Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment

Investing.com · Oct 8, 2026

Guggenheim reiterated a Buy rating and $78.00 price target on Enliven Therapeutics (NASDAQ:ELVN)

Guggenheim’s track record → Enliven Therapeutics Inc →

A fact about what Guggenheim published, as reported by Investing.com, not a recommendation from Dalsna Finance; Guggenheim is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.